** Shares of drug developer Arvinas ARVN.O fall 5.6% to $6.19, hitting all-time low
** Piper Sandler reduces price target to $24 from $67 on narrowed Vepdegestrant ESR1-mutant mBC approval; remains "overweight"
** Vepdegestrant, ARVN and Pfizer's PFE.N oral drug, failed to delay progression of breast cancer in patients with most common type of the disease in a late-stage trial last month
** Vepdegestrant only helped to extend progression-free survival in a subgroup of participants with a specific gene mutation, the company said in March
** ARVN is developing PROteolysis TArgeting Chimeras (PROTACs), which is a technique for the selective degradation of target proteins
** PROTACs are novel technology never tested in man that may fail in the clinic; ARVN's partnerships may falter and it may require additional capital - Piper Sandler
** Up to last close, stock had fallen nearly 66% YTD
(Reporting by Juby Babu in Mexico City)
((Juby.Babu@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。